spacer
home > ict > spring 2008 > credible risk management
PUBLICATIONS
International Clinical Trials

Credible Risk Management

Dr Gurdyal Kalsi of MDS Pharma Services assesses the value of clinical trial data monitoring committees taken from the contract research organisation perspective

The creation of data monitoring committees (DMCs), also known as data and safety monitoring boards, is almost a routine practice in randomised control trials performed specifically to register a human medicinal product. The primary purposes are to protect the patient participating in a trial setting and to uphold scientific credibility for the conduct of an experiment.

Several incidents recently reported in the media have led to product withdrawals and appear to be altering public perceptions around the rigours of conducting experiments on investigational agents in humans. The marketing of a product is based on a treatment effect size, established in a controlled setting, and safety, characterised in a limited pool of patients. In an era of evidence-based medicine, the accumulation of data across a number of trials may contradict an initial impression of stronger findings.

Furthermore, prospective observational and epidemiology study data may receive scientific and media interest far in excess of the original cited clinical research. What is more important than media hype is determining the need for a DMC based on predictable risks to trial participants. They provide a review opportunity at an early stage as part of a continuous risk management plan, thereby helping to counteract potential controversies related to the extent of due diligence afforded to known risks.

GUIDELINES

The establishment of a DMC must take into account a number of bodies and regulations: the relatively new EMEA Committee for Medicinal Products for Human Use guideline, effective from January 2006; guidance for clinical trial sponsors issued by the Food and Drug Administration (FDA); National Institutes of Health (NIH) policy for data and safety monitoring; World Health Organization (WHO) operational guidelines on DMCs; and the DAMOCLES (Data Monitoring Committees: Lessons, Ethics, Statistics) study group publication. (The DAMOCLES study group performed a comprehensive review of published literature on DMCs and developed a charter that covers all operating practices and procedures.) In addition, the International Conference on Harmonization (ICH) notes for guidance E3, E6 and E9 are considered relevant reading.

HOW TO ASSESS NEED

In the world of contract research organisations (CROs), clients often ask about the need to establish a clinical data monitoring committee. How can CROs help with the practicalities of running a DMC that monitors effectiveness and safety outcomes, and also makes recommendations that meet patient safety and regulatory requirements?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Gurdyal Kalsi is a Senior Pharmaceutical Physician with 15 years of experience in R&D assignments across biopharmaceutical drug and device engagements. Trained in Pharmaceutical Medicine from Cardiff University, UK, Gurdyal has been invited to present to various international congresses and seminars on pharmacovigilance and drug development topics. Gurdyal provides training in drug development, drug surveillance, medicines regulation and risk management. He is currently responsible for global provision of medical affairs and pharmacovigilance services within the global clinical development division of MDS Pharma Services
spacer
Dr Gurdyal Kalsi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

 
Industry Events

SCOPE Europe – Summit for Clinical Ops Executives Europe

17-18 September 2019, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical innovation leaders, clin ops execs, functional heads, category managers, and those responsible for the planning and management of clinical trials in Europe and the Rest of the World. The event will feature opening and closing plenary keynote sessions, five conference tracks, interactive breakout discussion groups, and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement